AMAG Pharma (AMAG) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
AMAG Pharmaceuticals (AMAG) Offer Positive Risk/Reward, Jefferies Says After Meeting with Management
February 11, 2015 6:38 AM ESTJefferies analyst Eun Yang reiterated a Buy rating and $55 price target on AMAG Pharmaceuticals (NASDAQ: AMAG) following a meeting with management.
Yang commented, "Focus on AMAG is timing for new asset acquisition & details on Makena life-cycle management strategies - key events for significant... More
